Reloadable multidrug capturing delivery system for targeted ischemic disease treatment

Jasmine P.J. Wu, Bill Cheng, Steve R. Roffler, David J. Lundy, Christopher Y.T. Yen, Peilin Chen, James J. Lai, Suzie H. Pun, Patrick S. Stayton, Patrick C.H. Hsieh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Human clinical trials of protein therapy for ischemic diseases have shown disappointing outcomes so far, mainly because of the poor circulatory half-life of growth factors in circulation and their low uptake and retention by the targeted injury site. The attachment of polyethylene glycol (PEG) extends the circulatory half-lives of protein drugs but reduces their extravasation and retention at the target site. To address this issue, we have developed a drug capture system using a mixture of hyaluronic acid (HA) hydrogel and anti-PEG immunoglobulin Mantibodies, which, when injected at a target body site, can capture and retain a variety of systemically injected PEGylated therapeutics at that site. Furthermore, repeated systemic injections permit "reloading" of the capture depot, allowing the use of complex multistage therapies. This study demonstrates this capture system in both murine and porcine models of critical limb ischemia. The results show that the reloadable HA/anti-PEG system has the potential to be clinically applied to patients with ischemic diseases, who require sequential administration of protein drugs for optimal outcomes.

Original languageEnglish
JournalScience Translational Medicine
Volume8
Issue number365
DOIs
Publication statusPublished - Nov 16 2016
Externally publishedYes

Fingerprint

Hyaluronic Acid
Pharmaceutical Preparations
Proteins
Hydrogel
Half-Life
Immunoglobulins
Intercellular Signaling Peptides and Proteins
Swine
Therapeutics
Ischemia
Extremities
Clinical Trials
Injections
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Reloadable multidrug capturing delivery system for targeted ischemic disease treatment. / Wu, Jasmine P.J.; Cheng, Bill; Roffler, Steve R.; Lundy, David J.; Yen, Christopher Y.T.; Chen, Peilin; Lai, James J.; Pun, Suzie H.; Stayton, Patrick S.; Hsieh, Patrick C.H.

In: Science Translational Medicine, Vol. 8, No. 365, 16.11.2016.

Research output: Contribution to journalArticle

Wu, JPJ, Cheng, B, Roffler, SR, Lundy, DJ, Yen, CYT, Chen, P, Lai, JJ, Pun, SH, Stayton, PS & Hsieh, PCH 2016, 'Reloadable multidrug capturing delivery system for targeted ischemic disease treatment', Science Translational Medicine, vol. 8, no. 365. https://doi.org/10.1126/scitranslmed.aah6228
Wu, Jasmine P.J. ; Cheng, Bill ; Roffler, Steve R. ; Lundy, David J. ; Yen, Christopher Y.T. ; Chen, Peilin ; Lai, James J. ; Pun, Suzie H. ; Stayton, Patrick S. ; Hsieh, Patrick C.H. / Reloadable multidrug capturing delivery system for targeted ischemic disease treatment. In: Science Translational Medicine. 2016 ; Vol. 8, No. 365.
@article{1d5479e5b1ea47f884c65c10ddc19182,
title = "Reloadable multidrug capturing delivery system for targeted ischemic disease treatment",
abstract = "Human clinical trials of protein therapy for ischemic diseases have shown disappointing outcomes so far, mainly because of the poor circulatory half-life of growth factors in circulation and their low uptake and retention by the targeted injury site. The attachment of polyethylene glycol (PEG) extends the circulatory half-lives of protein drugs but reduces their extravasation and retention at the target site. To address this issue, we have developed a drug capture system using a mixture of hyaluronic acid (HA) hydrogel and anti-PEG immunoglobulin Mantibodies, which, when injected at a target body site, can capture and retain a variety of systemically injected PEGylated therapeutics at that site. Furthermore, repeated systemic injections permit {"}reloading{"} of the capture depot, allowing the use of complex multistage therapies. This study demonstrates this capture system in both murine and porcine models of critical limb ischemia. The results show that the reloadable HA/anti-PEG system has the potential to be clinically applied to patients with ischemic diseases, who require sequential administration of protein drugs for optimal outcomes.",
author = "Wu, {Jasmine P.J.} and Bill Cheng and Roffler, {Steve R.} and Lundy, {David J.} and Yen, {Christopher Y.T.} and Peilin Chen and Lai, {James J.} and Pun, {Suzie H.} and Stayton, {Patrick S.} and Hsieh, {Patrick C.H.}",
year = "2016",
month = "11",
day = "16",
doi = "10.1126/scitranslmed.aah6228",
language = "English",
volume = "8",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "365",

}

TY - JOUR

T1 - Reloadable multidrug capturing delivery system for targeted ischemic disease treatment

AU - Wu, Jasmine P.J.

AU - Cheng, Bill

AU - Roffler, Steve R.

AU - Lundy, David J.

AU - Yen, Christopher Y.T.

AU - Chen, Peilin

AU - Lai, James J.

AU - Pun, Suzie H.

AU - Stayton, Patrick S.

AU - Hsieh, Patrick C.H.

PY - 2016/11/16

Y1 - 2016/11/16

N2 - Human clinical trials of protein therapy for ischemic diseases have shown disappointing outcomes so far, mainly because of the poor circulatory half-life of growth factors in circulation and their low uptake and retention by the targeted injury site. The attachment of polyethylene glycol (PEG) extends the circulatory half-lives of protein drugs but reduces their extravasation and retention at the target site. To address this issue, we have developed a drug capture system using a mixture of hyaluronic acid (HA) hydrogel and anti-PEG immunoglobulin Mantibodies, which, when injected at a target body site, can capture and retain a variety of systemically injected PEGylated therapeutics at that site. Furthermore, repeated systemic injections permit "reloading" of the capture depot, allowing the use of complex multistage therapies. This study demonstrates this capture system in both murine and porcine models of critical limb ischemia. The results show that the reloadable HA/anti-PEG system has the potential to be clinically applied to patients with ischemic diseases, who require sequential administration of protein drugs for optimal outcomes.

AB - Human clinical trials of protein therapy for ischemic diseases have shown disappointing outcomes so far, mainly because of the poor circulatory half-life of growth factors in circulation and their low uptake and retention by the targeted injury site. The attachment of polyethylene glycol (PEG) extends the circulatory half-lives of protein drugs but reduces their extravasation and retention at the target site. To address this issue, we have developed a drug capture system using a mixture of hyaluronic acid (HA) hydrogel and anti-PEG immunoglobulin Mantibodies, which, when injected at a target body site, can capture and retain a variety of systemically injected PEGylated therapeutics at that site. Furthermore, repeated systemic injections permit "reloading" of the capture depot, allowing the use of complex multistage therapies. This study demonstrates this capture system in both murine and porcine models of critical limb ischemia. The results show that the reloadable HA/anti-PEG system has the potential to be clinically applied to patients with ischemic diseases, who require sequential administration of protein drugs for optimal outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84995653333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995653333&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aah6228

DO - 10.1126/scitranslmed.aah6228

M3 - Article

C2 - 27856799

AN - SCOPUS:84995653333

VL - 8

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 365

ER -